NCT05823779 (HSVHIV) is a clinical trial of Blood draw in HIV Disease, sponsored by Global Research Institute.

Who is sponsoring NCT05823779?

NCT05823779 is sponsored by Global Research Institute.

What drugs are being tested in NCT05823779?

Interventions in NCT05823779: Blood draw.

What condition does NCT05823779 study?

NCT05823779 studies HIV Disease, Herpes Simplex 1, Herpes Simplex 2.

Is NCT05823779 still recruiting?

NCT05823779 is currently status unknown. Last updated 21 April 2023.

Last reviewed 2023-04-21 · How we verify

NCT05823779: HSVHIV

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A 48 Week Observational Study of the Frequency of Symptomatic Herpes Virus I and II in HIV Infected Subjects

Status unknown Last updated 21 April 2023

What this trial tests

trial testing Blood draw in HIV Disease in 50 participants. Status unknown.

Timeline

1 April 2022

Primary endpoint
31 December 2024

1 April 2025

Quick facts

Lead sponsor	Global Research Institute
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	50
Start date	1 April 2022
Primary completion	31 December 2024
Estimated completion	1 April 2025
Sites	1 location across United States

Drugs / interventions tested

Blood draw — full drug profile →

Conditions studied

HIV Disease — all drugs for HIV Disease →
Herpes Simplex 1 — all drugs for Herpes Simplex 1 →
Herpes Simplex 2 — all drugs for Herpes Simplex 2 →

Sponsor

Global Research Institute

Who can join

18 and older, any sex, with HIV Disease or Herpes Simplex 1. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is an observational, cohort, prospective study looking at the frequency of Herpes Simplex Virus (HSV) 1 and or 2 outbreaks in HIV positive patients who's HIV virus is controlled on highly active anti-retroviral therapy. We will be enrolling fifty (50) patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Blood draw

Trials testing the same drug.

NCT07518784 — Accurate Point of Care Liver Disease Diagnostics (Phase 2) · recruiting
NCT07252622 — Progesterone Levels and Frozen Embryo Transfer Outcomes · not yet recruiting
NCT07382076 — Clinical Evaluation of the i-STAT ACTpro Cartridge in an Adult Population · active not recruiting
NCT06011824 — A Study of Effect of Megakaryocytes and Platelets in Breast Cancer · completed
NCT05912400 — Evaluating Mitochondrial Dysfunction in Patients With Neurofibromatosis Type 1 · completed

Other recruiting trials for HIV Disease

Currently open trials in the same condition.

NCT07292792 — The Unlocking PrEP Study: Integration of Peer Health Navigation Into Comprehensive Re-entry Services · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05823779 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Global Research Institute
Last refreshed: 21 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05823779.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing